Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
In vitro T Cell Activation Assay to Predict Immunogenicity of Biotherapeutic Products
Thursday, October 21, 2021 · 4:40 p.m. · Eastern Time (US & Canada)
About This Webinar
The development of anti-drug antibodies (ADAs) is an undesirable potential outcome of the administration of biotherapeutics. We have developed a novel method that provides a rapid and simple preclinical test of the immunogenic potential of a new candidate biotherapeutic or biosimilar. Implementation of this approach during biotherapeutic research and development enables rapid elimination of candidates that are likely to cause ADA-related adverse events and detrimental consequences.
Who can view: Everyone
Webinar Price: Free
Featured Presenters
Scientist
Dr. Sivan Cohen is a scientist in the Department of BioAnalytical Sciences (BAS) at Genentech. A trained immunologist, She received her Ph.D. in Immunology from the Weizmann Institute of Science and conducted her post-doctoral training in Duke University. Sivan joined Genentech in 2017, and currently leads the development and implementation of in silico and in vitro bioanalytical assays to support evaluation of immunogenicity potential of Genentech’s biotherapeutic products.
Hosted By
Recommended